By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Baxalta 

650 E Kendall Street

Cambridge  Massachusetts    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

YEAR FOUNDED:

2015

LEADERSHIP:

CEO: Ludwig Hantson

CFO: Robert Hombach

CSO (Scientific): John Orloff

JOBS:

Please click here for Baxalta job opportunitites.

CLINICAL TRIAL:

Please click here for clinical trial information.


PRODUCTS:
All Products

FOLLOW BAXALTA
:



Key Statistics


Email:
Ownership: Public

Web Site: Baxalta
Employees: 16,000
Symbol: BXLT
 



Industry
Biotechnology






Company News
In 3Q Report, Shire (SHPG) Breaks Out Data From Baxalta (BXLT) Acquisition and Announces Several Program Terminations 11/1/2016 6:09:03 AM
Shire (SHPG) Pays CTI BioPharma $10.3 Million to Terminate Cancer Deal it Picked Up From Baxalta (BXLT) 10/24/2016 5:52:16 AM
Editas Medicine (EDIT) Brings on New Execs From Sanofi Genzyme (SNY), Novartis AG (NVS), Baxalta (BXLT) and Bristol-Myers Squibb (BMY) 10/5/2016 7:19:35 AM
Shire (SHPG) Terminates a Couple of Biosimilar Deals Made by Baxalta (BXLT) 9/27/2016 6:35:57 AM
SEC Filing Reveals Shire (SHPG) is Ready to Punt $172 Million Baxalta (BXLT) Deal With CTI BioPharma 9/20/2016 6:43:25 AM
Acadia (ACAD) Scores Former Baxalta (BXLT) Exec as New CFO 8/24/2016 7:10:00 AM
As Baxalta (BXLT) Merger Closes, Shire (SHPG) Talks Job Cuts Worth $700 Million 8/11/2016 2:01:59 PM
Shire (SHPG) Kills Baxalta (BXLT)'s Hemophilia B Program; Clears Path for BioMarin (BMRN), Spark Therapeutics (ONCE) and uniQure (QURE) 8/3/2016 7:26:00 AM
As Shire (SHPG) Closes on Baxalta (BXLT), David Meek Takes the Helm at Ipsen (IPN.PA) 7/11/2016 6:16:09 AM
As Stock Rises and Baxalta (BXLT) Merger Closes, Shire (SHPG) Opens New HQ in Massachusetts with 800 Jobs 6/29/2016 6:43:18 AM
12345678910...
//-->